# Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

> **NCT01033760** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 90 (actual)

## Conditions studied

- HIV-1 Infections

## Interventions

- **DRUG:** raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine
- **DRUG:** darunavir; ritonavir; emtricitabine/tenofovir

## Key facts

- **NCT ID:** NCT01033760
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2013-07
- **Final completion:** 2013-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2014-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033760, "Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01033760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*